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Abstract 
Previously, we have shown that three different m R N A species of 4.3 kb, 1.8 kb and 1.4 kb, 
related to human complement factor H , are constitutively expressed in the human liver. 
Probing w i t h our c D N A clone H-46 which represents 920 bp of the 3' end of the 4.3 kb 
m R N A of factor H on human liver R N A , we always detected the 4.3 kb and the additional, 
abundantly expressed m R N A species of 1.4 kb in length, indicating that the 1.4 kb transcript is 
highly homologous to the 3' end of the classical factor H m R N A of 4.3 kb. Using H-46 as a 
probe, several c D N A clones were isolated from a liver c D N A library and sequenced. The open 
reading frame of the novel m R N A species encodes a peptide consisting of five internal short 
consensus repeat motifs (SCR), identifying the translational product to be a member of the 
SCR family. Sequence comparison wi th c D N A clones derived from liver R N A of a different 
donor provided evidence for variability in the factor H related proteins encoded by the 1.4 kb 
m R N A species. 
Interestingly, this variability was found to be restricted to the three carboxyterminal SCR 
domains. Expression data indicate that our variant is not recognized by the monoclonal 
antibody 3D11. 
Introduction 
Factor H is a regulatory protein of the complement system which 
controls the alternative pathway of complement activation by competing 
for the interaction of C3b wi th factor B and dislodging the Bb fragment of 
factor B from the active alternative pathway convertase (C3bBb) (1-3). 
Factor H also serves as a cofactor for factor I in the conversion of C3b to 
inactivated C3b, iC3b (4). The binding site for C3b has been located on a 
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M r 38,000 aminoterminal fragment obtained by limited tryptic digestion of 
the major M r 150,000 factor H serum protein (5). 
In addition, this M r 38,000 fragment shows a cofactor activity in the 
factor I-mediated conversion of C3b to iC3b, while the remainder of the 
molecule is inactive in this respect (6). 
For human factor H three different m R N A species are abundantly 
expressed in liver: 4.3 kb, 1.8 kb and 1.4 kb (7). The 4.3 m R N A codes for 
the major factor H serum protein of M r 150,000 - termed H gp!50 - and 
has been completely sequenced (8, 9). The sequence analysis of the 1.8 kb 
m R N A showed that this species is largely identical to the 5' portion of the 
4.3 kb m R N A (8-11). A partial analysis of the factor H gene strongly 
suggests that the 1.8 kb and the 4.3 kb m R N A arise by alternative splicing 
from a single structural gene (12). 
Factor H has been shown to be highly homologous to other regulatory 
proteins of the complement system such as the C4 binding protein (C4bp), 
the decay accelerating factor (DAF), the membrane cofactor protein (MCP) 
and the complement receptors type 1 (CR1) and type 2 (CR2). Characteris-
tically, the amino acid sequence of these proteins has a structure of 
numerous internal domains, termed «short consensus repeats» (SCR). Each 
SCR covers a stretch of approximately 60 amino acids with a framework of 
four completely conserved cysteine residues along with highly conserved 
residues for glycine, tryptophan, tyrosine and proline (13-15). 
The translational product of the 4.3 kb m R N A - Hgpl50 - is composed 
of twenty such SCRs, while the 1.8 kb m R N A encodes the first seven 
repeating units of the aminoterminal portion of Hgpl50, plus four unique 
amino acids at the COOH-terminal sequence. The genes encoding factor H 
and the other above-mentioned complement regulatory proteins have been 
localized to chromosome 1 forming a tightly linked gene cluster named the 
RCA (regulation of complement activation) cluster (16). 
Recently, we identified a novel truncated factor H protein as the likely 
translational product of the 1.8 kb m R N A in fresh human plasma by 
Western blot analysis with monoclonal and polyclonal antibodies directed 
against the aminoterminal portion of H (7). 
After purification by combined affinity chromatography and HPLC, we 
were able to show that this novel truncated factor H serum protein also has 
cofactor activity for the cleavage of C3b (17). The identity of this novel, 
truncated factor H protein with the translational product of the 1.8 kb 
m R N A was confirmed by eucaryotic expression of a full length c D N A 
clone of the 1.8 kb factor H m R N A species (9). 
We have previously shown that in human liver R N A , a third factor H 
related m R N A species of 1.4 kb strongly hybridizes to our c D N A clone 
H-46 (H-46 represents 920 basepairs of the 3' end of the 4.3 kb mRNA) . 
This m R N A species is only detectable in liver tissue, while the 4.3 kb and 
the 1.8 kb mRNA species of factor H are also expressed in fibroblasts, 
monocytes, endothelial cells and lung tissue (18). 
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In this report, we present a novel nucleotide sequence (H-69) for this 
factor H-related m R N A species and compare the sequence to other c D N A 
transcripts which we isolated in parallel from a different c D N A library (19). 
Procaryotic expression indicates that the significant variation observed for 
the factor H-related 1.4 kb m R N A leads (in the case of H-69) to a loss of 
the epitope recognized by monoclonal antibody 3D 11 which was shown to 
react wi th the classical factor H molecule of M r 150,000 and the two 
polypeptides encoded by the other variants of this factor H-related 1.4 kb 
m R N A species. 
Materials and Methods 
cDNA cloning and sequencing of H-69 and H-69/2 
The c D N A clone H-69 was isolated from a commercially available human liver c D N A 
library in X-gtl0 (Clontech, Palo Al to , C A , USA) which was screened wi th our factor H -
specific c D N A clone H-46. c D N A clone H-69/2 was isolated from a human liver primer 
extension c D N A library in which the oligo dT primer was replaced by a 21 bp long 
oligonucleotide, termed oligo 1.4/1,(3' G C C CCG A C C A G G T G G G G A G G G 5') derived 
from H-69 (see Fig. 2) to initiate the synthesis of the first strand. For the c D N A synthesis, 
poly ( A + ) R N A was selected from total R N A preparations of human liver tissue using the 
« m R N A Purification Kit» (Pharmacia, Freiburg, Germany). First and second strand synthesis 
was carried out using the «You-Prime c D N A Synthesis Kit» (Pharmacia). Double-stranded 
c D N A was subcloned in X.-gt 10 using the « c D N A cloning systemA-gtl0» (Amersham, 
Aylesbury, U K ) . The library was screened with a second 18 bp long oligonucleotide, termed 
oligo 1.4/2, (3* C T A C A C A A A C A G G A C T T C 5 ' ) derived from H-69 5 to oligo 1.4/1. 
From five hybridizing plaques, H-69/2 showing the largest c D N A insertion was analyzed 
further. The c D N A insertions contained in H-69 and H-69/2 were amplified in a polymerase 
chain reaction (PCR) using «X-gtl0 Screening Amplimer sets» (Clontech). They were then 
digested with either EcoRI , or EcoRI and Rsal, or EcoR I and Hind I I I and subcloned into 
M13 for sequencing by the Sanger dideoxy chain termination method (20). The sequencing 
strategy chosen for H-69 and H-69/2, is shown in Figure 1. Sequencing of H-69 and H-69/2 
was performed with T7 polymerase and the reagent kit (Pharmacia). 
Northern blot analysis 
From human liver tissue, R N A was prepared according to the method of CHIRCAVIN et al. 
(21). Twenty (ig of total R N A was separated on a formaldehyde-containing agarose gel and 
blotted to Hybond N nylon filters (Amersham). Agarose gel electrophoresis, R N A transfer 
and hybridization of the blots were done by standard techniques (20). The D N A probes were 
labeled with P" -dATP using the random priming method (22). 
The probes utilized in these studies are H-69/2 (coding for the novel 5' sequence of the 
factor H related 1.4 kb m R N A ) , a 292 bp Hind I I I subfragment of H-69 (representing the 3' 
end of H-69), and a 718 bp long A l u l subfragment of the factor H specific c D N A clone R2a 
(8) which codes for SCR domains 12-16. 
Hybridization was performed at 65 °C in the absence of formamide. The final washing step 
was done in 0.1 xSSC for 1 h at 65 °C. 
Procaryotic and eucaryotic expression and Western blot analysis 
For procaryotic expression, the c D N A contained in H-69 was digested with EcoRI , 
yielding a 1060 bp-long subfragment of H-69 which encodes, wi th the exception of 13 
aminoterminal amino acids, the mature translational product of the 1.4 kb m R N A species. 
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This fragment was subcloned into the EcoRI site of the procaryotic expression vector pAX 
(23). The expression of clone p A X - H - 6 9 , containing the EcoRI fragment of H-69 in the 
correct reading frame and orientation, was induced by adding 1 ml of a 100 m M isopropyl-ß-
D-thiogalactoside solution (IPTG) to a 100 ml bulk culture for at least 3 h before harvesting. 
The expression of the fusion protein encoded by H-46 (which was isolated from a human 
liver library cloned in the procaryotic expression vector pEX2 (11)) was induced according to 
the method by STANLEY and L u z i o (24) by shifting a bulk culture of H-46 to 42 °C for 90 min. 
The bacteria were pelleted and lysed in 1/10 of the original volume of 50 m M TRIS/HC1 p H 
6.8 containing 5% SDS, 1 % mercaptoethanol, 10% glycerol. 
The eucaryotic expression of the c D N A clone pFH1.4a was achieved by COS-cell transfec-
tion. Therefore, pFH1.4a and the vector C D M 8 as control D N A were transfected into COS 
cells by electroporation using the «Gene PulserTM apparatus» (Bio-Rad, Munich, Germany) 
following the recommendations of the supplier. Briefly, 0.8 ml of COS cell suspension (1 x 107 
cells/ml) were mixed with 60 jig D N A . Electroporation was performed in 272 m M sucrose, 7 
m M N a 2 H P 0 4 p H 7.4 and 1 m M M g C l 2 with 380 V and 250 F in the cold. The cells were then 
diluted with DMEM/25 m M HEPES medium containing 10 % FCS and cultured in 9 cm petri 
dishes. After 24 h, the medium was changed to D M E M containing 1 x Nutridoma H U 
(Boehringer Mannheim). Supernatants were collected 72 h after the pulse, concentrated 
20-fold, and assayed for the expression the translational product of 1.4 kb m R N A . 
For Western blot analysis, 80 ui of concentrated supernatant of COS cell transfectants, 2 u.1 
of serum and 20 ul of the bacterial lysates were electrophoresed on a 7.5% SDS-polyacryl-
amide gel and blotted to nitrocellulose according to the method of T O W B I N et al. (25). 
Individual lanes were stained with mAb 3D11 and a polyclonal goat anti-factor-H-antibody 
using peroxidase-conjugated anti-mouse IgG and peroxidase-conjugated anti-goat IgG, 
respectively, according to standard procedures. 
Results 
cDNA cloning and sequencing of H-69 and H-69/2 
To isolate c D N A clones representing the unknown factor H related 
m R N A species of 1.4 kb, H-46 was used to screen a human liver c D N A 
library in \-gt\0. From 60,000 plaques, twenty hybridizing clones were 
isolated. From these, c D N A insertions were amplified in a polymerase 
chain reaction (PCR) using oligonucleotides corresponding to the poly-
linker region of X-gtl0. Amplified inserts were digested with EcoRI, 
subcloned in the bacteriophage M l 3 and sequenced from both ends (see 
Fig. I ) . From those, nineteen were identified to be incomplete transcripts of 
the known 4.3 kb mRNA, while one - designated H-69 - was shown to 
have a 35 portion almost identical to that of the 4.3 kb mRNA, preceded by 
a unique 5* portion with only a slight degree of homology to the sequence 
of factor H (see Fig. 2). 
Since neither a 5' untranslated region nor a translational start codon was 
contained at the 5' end of H-69, we used an oligonucleotide (3* GCC CCG 
A C C A G G T G G GGA GGG 5') corresponding to the 5' portion of the 
H-69 sequence for a primer extension c D N A synthesis in order to obtain a 
c D N A covering the full length of the 1.4 kb m R N A species. One primer 
extension clone, termed H-69/2, was sequenced extending the 5' end of 
H-69 for a length of 166 bp (see Fig. 1). 
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Figure 1. Subcloning and sequencing strategy used for the sequence analysis of the c D N A 
clones H-69/1 and H-69/2. The arrows mark the extent and direction of the D N A sequence 
determination below the restriction map wi th the following enzymes: E = EcoRI ; R = Rsal; 
H = Hind I I I . H-69/1 and H-69/2 overlap for a stretch of 270 bp. 
H-69 /1 
The complete nucleotide sequence and the derived amino acid sequence, 
encoded by the c D N A clones H-69 and H-69/2 are shown in Figure 2. The 
combined nucleotide sequence of 1173 bp revealed an open reading frame of 
993 bp starting with A T G at position 22 and ending with a stop codon 
(TAG) at position 1012. The coding sequence of the 1.4 kb m R N A covered 
by H-69 and H-69/2 is flanked by a 5' and a 3' untranslated region of 21 and 
162 nucleotides, respectively. The 3' untranslated region includes a poly-
adenylation signal ( A T T A A A ) located 40 nucleotides downstream from the 
translational termination codon. With exception of four nucleotide 
exchanges and one insertion (see Fig. 2), the sequence of the 3* untranslated 
region of H-69 is identical to the 3' untranslated region of the 4.3 kb 
m R N A species of factor H , represented by H-46 . 
Moreover, the sequence homology extends into the protein coding region 
which is nearly identical for a stretch of 557 bp encoding the three SCR 
domains SCR 18, 19, 20 of classical factor H (see Fig. 2). Regarding the 
criteria given by V O N H E I J N F (26), the peptide sequence, encoded by the 
open reading frame of the 1.4 kb m R N A species, indicates an 18 amino 
acid-long leader peptide prior to the 312 amino acids of the mature protein. 
Including the leader sequence, the molecular weight for the primary 
translational product was calculated to be 37,663 and 35,750 for the mature 
protein, respectively. As shown in Figure 3, the mature protein is composed 
of five approximately 60-amino acid-long short consensus repeats (SCR) 
which are typically observed in complement regulatory proteins (13-16). 
The three carboxyterminal SCRs of the protein encoded by H-69 and H -
69/2 show five amino acid exchanges in comparison to the carboxyterminal 
SCR's of the major M r 150,000 factor H protein, namely SCR-18-20. In 
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comparison, only a low degree of homology was observed between the 
SCRs 6 and 7 of the classical factor H protein of M r 150,000 and the two 
novel SCR domains 1 and 2 of the aminoterminal portion of the protein 
encoded by the 1.4 kb mRNA. 
Interestingly, the derived amino acid sequence of H-69 contains only one 
potential glycosylation site (NIS) in position 108, while the two other 
variants of the 1.4 kb m R N A (pFH1.4a and b) and H-46 (representing the 
4.3 kb m R N A species) encode an additional, potential glycosylation site 
(NWT) in position 176. 
M W L L V S V I L I S R I 
H-69 ATAAGATTGGAACTACCAAGCATGTGGCTCCTGGTCAGTGTAATTCTAATCTCACGGATA 60 
pFH1.4a 96 
1 10 
S S V G G E A T F C D F P K I N H G I L 
H-69 TCCTCTGTTGGGGGAGAAGCAACATTTTGTGATTTTCCAAAAATAAACCATGGAATTCTA 12 0 
pFH1.4a 156 
20 30 
Y D E E K Y K P F S Q V P T G E V F Y Y 
H-69 TATGATGAAGAAAAATATAAGCCATTTTCCCAGGTTCCTACAGGGGAAGTTTTCTATTAC 18 0 
pFH1.4a 216 
40 50 
S C E Y N F V S P S K S F W T R I T C T 
H-69 TCCTGTGAATATAATTTTGTGTCTCCTTCAAAATCATTTTGGACTCGCATAACATGCACA 24 0 
pFH1.4a 276 
60 70 
E E G W S P T P K C L R L C F F P F V E 
H-69 G AAGAAGGATGGTCACCAACACCAAAGTGTCTCAGACTGTGTTTCTTTCCTTTTGTGGAA 300 
pFH1.4a 336 
80 90 
N G H S E S S G Q T H L E G D T V Q I I 
H-69 AATGGTCATTCTGAATCTTCAGGACAAACACATCTGGAAGGTGATACTGTGCAAATTATT 3 60 
pFH1.4a 396 
o l i g o 
1.4/2 
100 110 
C N T G Y R L Q N N E N N I S C V E R G 
H-69 TGCAACACAGGATACAGACTTCAAAACAATGAGAACAACATTTCATGTGTAGAACGGGGC 420 
pFH1.4a 456 
o l i g o GCCCCG 
1.4/1 
120 130 
W S T P P K C R S T D T S C V N P P T V 
H-69 TGGTCCACCCCTCCCAAATGCAGGTCCACTGACACTTCCTGTGTGAATCCGCCCACAGTA 4 8 0 
pFH1.4a 516 
H-46 C 216 
o l i g o ACCAGGTGGGGAGGG 
1.4/1 
140 150 
Q N A H I L S R Q M S K Y P S G E R V R 
H-69 CAAAATGCTCATATACTGTCGAGACAGATGAGTAAATATCCATCTGGTGAGAGAGTACGT 54 0 
pFH1.4a T G 576 
H-46 T G 276 
Y V 
160 170 
Y Q C R S P Y E M F G D E E V M C L N G 
H-69 TATCAATGTAGGAGCCCTTATGAAATGTTTGGGGATGAAGAAGTGATGTGTTTAAATGGA 600 
pFH1.4a 636 
H-46 336 
Figure 2. Nucleotide and deduced amino acid sequence of c D N A clones H-69 and H-69/2 in 
comparison with another variant of the human factor related 1.4 kb m R N A species (pFHl .4a) 
and the 4.3 kb mRNA. species represented by our c D N A clone H-46. 
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Northern blot analysis with H-69 and H-69/2 and fragments specific for 
the related 1.4 and the 4.3 kb mRNA species of factor H 
To examine whether H-69 is a faithful transcript of the 1.4 m R N A 
species, we established 3' and 5' specific subfragments of H-69 to probe 
human liver RNA. 
A 3' specific subfragment was isolated by using an internal unique 
Hind Ill-restriction site in position 882 resulting in a 292 bp 3' fragment. 
180 190 
N W Q E P P Q C K D S Q G K C G P P P P 
H-69 AACTGGCAGGAACCACCTCAATGCAAAGATTCTCAGGGAAAATGTGGGCCCCCTCCACCT 660 
pFH1.4a AC AC 696 
H-46 AC ACA 396 
T T 
200 210 
I D N G D I T S F P L S V Y A P A S S V 
H-69 ATTGACAATGGGGACATTACTTCATTCCCGTTGTCAGTATATGCTCCAGCTTCATCAGTT 720 
pFH1.4a 756 
H-46 456 
220 230 
E Y Q C Q N L Y Q L E G N K R I T C R N 
H-69 GAGTACCAATGCCAGAACTTGTATCAACTTGAGGGTAACAAGCGAATAACATGTAGAAAT 780 
pFH1.4a 816 
H-4 6 516 
240 250 
G Q W L E P P K C L H P C V I S R E I M 
H-69 GGACAATGGCTAGAACCACCAAAATGCTTACATCCGTGTGTAATATCCCGAGAAATTATG 84 0 
pFH1.4a TC 876 
H-46 TC 576 
S 
260 270 
E N Y N I A L R W T A K Q K L Y L R T G 
H-69 GAAAATTATAACATAGCATTAAGGTGGACAGCCAAACAGAAGCTTTATTTGAGAACAGGT 900 
pFH1.4a 936 
H-46 C 636 
280 290 
E S A E F V C K R G Y R L S S R S H T L 
H-69 GAATCAGCTGAATTTGTGTGTAAACGGGGATATCGACTTTCATCACGTTCTCACACATTG 9 60 
pFH1.4a T 996 
H-46 T T 696 
V 
300 310 
R T T C W D G K L E Y P T C A K R * 
H-69 CGAACAACATGTTGGGATGGGAAACTGGAGTATCCAACTTGTGCAAAAAGATAGAATCAA 102 0 
pFH1.4a 1056 
H-46 756 
H-69 TCATAAAATGCACACCTTTATTCAGAACTTTAGTATTAAATCAGTTCTTAATTTCATTTT 1080 
pFH1.4a A 1116 
H-46 G C 816 
H-69 TAA-GTATTGTTTTACTCCTTTTTATTCATACGTAAAATTTTGGATTAATTGGTGAAAATG 114 0 
pFH1.4a T 1176 
H-46 .T.T T 876 
H-69 TAATTATAAGCTGAGACCGGTGGCTCTCTTCTT 117 3 
pFH1.4a 1209 
H-46 936 
The sequences corresponding to the oligonucleotides oligo 1.4/1 (used for the primer extension 
c D N A synthesis of H-69/2) and oligo 1.4/2 (used for screening the primer extension c D N A 
library) are marked. 
MWLLVSVILISRISSVGG EATfß-Dfftl— 
RL: 
TS 
DSQGK: 
FP-FVE--
:i/-N"TVQ 
MGILYDEEKYKPFS 
GH--
HlftHIL-
GDIT—S 7PLSV-
J-ESSGQTHLEGDTV3II 
•QVP-TG-WYYSE 
•PSGERVRYQ-
yhP-ASSI/EYQ 
HP: VISREIMENY IALRWTAKQKL YOTSAEFV-CKRGYUSSRSHTL--RTT: J)GKLEY
3
ICf\KR 20 
-E-MFVSPSKSFWTRIT:TEE 
fcWLY 
NNENNIS-
(BMFGDEEVM--
-QLEGNK--RIT:RN-G3(I 
UER 
LN 
-SPTPC 
—STP
3
< 
--QEPP3 
--LEP
3
< 
1' 
fcSTD 2' 
18 
19 
Figure 3. Assignment of the protein sequence derived from H-69 and H-69/2 to five homology subunits of about 60 amino acids each. Identical amino acids 
present in several of the five homologous regions are boxed. Gaps denoted by «-» have been introduced to maximize homology and to allow space for the 
regions with short inserted sequences. The potential glycosylation site (NIS) in position 108 is underlined. 
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h u m a n l i v e r RNA 
9.5 > 
7.5 > 
4.4 > 
2.4 > 
1.4 
kb 
a b c 
Figure 4. Northern blots of human liver R N A hybridized with different c D N A fragments. 
Twenty ug of total R N A each was separated on an agarose gel. Lane a was hybridized with H -
69/2 coding for the novel 5' sequence of the 1.4 kb m R N A species. Lane b was hybridized with 
a 292 bp long Hind I I I restriction fragment representing the 3' coding and the 3' untranslated 
region of H-69. Lane c was hybridized with a 718 bp A l u I fragment representing the coding 
region for SCR 12-16 of the 4.3 kb m R N A of factor H . 
This subfragment completely represents the 3' untranslated region in 
addition to 130 bp of the SCR 20 coding region of H-69. This 3 J fragment of 
H-69 hybridizes with both, the 4.3 and the 1.4 kb m R N A species (see Fig. 
4, lane b). This result confirms the c D N A sequencing data showing that 
both mRNA species share the same 3* region. 
Probing primer extension clone H-69/2 (coding for the novel 5' sequence 
of the 1.4 kb derived c D N A ) on total liver R N A , we exclusively detected 
the 1.4 kb m R N A species (see Fig. 4, lane a). This result shows that the 1.4 
kb mRNA must have given rise to the unique 5' sequence linked to a 
segment which is shared by both, the 4.3 kb factor H m R N A and related 
1.4 kb m R N A species. 
Further confirmation for the direct linkage of SCR 1 and 2 of the 1.4 kb 
mRNA to the conserved sequence of SCR 18, 19 and 20 was obtained by 
probing with a subfragment of the 4.3 kb c D N A (718 bp A l u l fragment) 
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representing the coding region for SCR domains 12 to 16 (see Fig. 6). This 
probe exclusively hybridizes with the 4.3 kb and not with the 1.4 kb 
m R N A species (see Fig. 4, lane c). 
Thus, the Northern blot results confirm that H-69 and H-69/2 are 
faithful reverse transcripts of the 1.4 kb m R N A species sharing a nearly 
identical 3' portion with the 4.3 kb long factor H mRNA, followed by a 
novel 5' portion of 456 nucleotides. 
Procaryotic expression and Western blot analysis of the recombinant 
proteins encoded by H-69 and H-46 
For procaryotic expression, H-69/1 was subcloned into the EcoR I site of 
the procaryotic expression vector p A X 4 C . 
Clone pAX-H-69, which was shown to contain the insertion in the 
correct reading frame and orientation, was used for expression of the 
ß-galactosidase/H-69 fusion protein. In parallel, the expression of the 
fusion protein encoded by H-46 (cloned in pEX2 (11)) was induced 
according the method by STANLEY and Luzio (24). 
1 2 3 4 5 6 7 8 9 
Figure 5. Western blot analysis of the translational products encoded by different variants of 
the 1.4 kb m R N A species, the 3' coding region of the 4.3 kb m R N A of factor H , and of the 
translational products represented in human plasma. In lanes l and 4, bacterial lysate and the 
galactosidase encoded by pEX2 (lane l ) and p A X C4 (lane 4) were exposed to a polyclonal 
anti-factor H-antibody as a negative control. The fusion protein encoded by H-46 was stained 
with the polyclonal (lane 2) and the monoclonal anti-factor-H-antibody mAb 3D 11 (lane 3) 
while the fusion protein encoded by pAX-H-69 was only stained with the polyclonal antibody 
(lane 5), but not with m A b 3 D l l (lane 6). In lane 8, concentrated supernatant from COS cells 
transfected with pFH1.4a was stained with m A b 3 D l l , while supernatant from COS cells 
transfected with the vector C D M 8 alone remained blank (lane 7). In lane 9, 2 id of human 
plasma were stained with m A b 3 D l l . 
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Figure 6. Diagram of the three m R N A species related to human factor H . The specific 
untranslated regions and the SCR repeat units encoded by the different m R N A species are 
boxed. The c D N A clones (pCH4.3 and H-46 for the 4.3 kb m R N A , pCH1.8 for the 1.8 kb 
m R N A , H-69 and H-69/2 for the 1.4 kb m R N A ) and subfragments representing the different 
m R N A species are marked as lines. 
After induction, the bacteria were lysed and the total lysate was separated 
on a 7.5 % SDS-polyacrylamide gel. To exclude any possible crossreactivity 
of the antibodies used with ß-galactosidase or bacterial polypeptides in the 
Western blot analysis, proteins were also prepared from a p A X C 4 clone 
and a pEX2 clone without any c D N A insertion. As a positive control, 
human plasma was collected from four different donors in presence of 
0.5 mM PMSF, 5 m M E D T A and 50 m M 6-aminohexanoic acid (EACA) to 
prevent any possible protein degradation. As shown in Figure 5, the 
polyclonal antibody stained both fusion proteins encoded by H-46 and 
pAX-H-69 while the extracts of the vector recombinant bacteria remained 
blank. 
In contrast, the monoclonal antibody 3D 11 only stained the fusion 
protein generated by H-46, but not the fusion protein of pAX-H-69 (Fig. 5, 
lanes 3 and 6). Again, the negative controls remained blank whereas, 
m A b 3 D l l stained the classical M r 150,000 factor H protein, the two 
polypeptides of M r 37,000 and 39,000 in human plasma, and the eucaryotic 
expression products of pFH1.4a, which is a full length c D N A clone of the 
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1.4 kb factor H mRNA, but differs in five amino acid residues from the 
H-69 sequence (see Fig. 5). 
Discussion 
The Northern blot analysis and the c D N A sequencing have confirmed 
that the overlapping c D N A clones H-69 and H-69/2 represent faithful 
reverse transcripts of a novel factor H-related mRNA species of 1.4 kb, 
which is abundantly expressed in human liver. The open reading frame of 
H-69 codes for a peptide with one potential N-glycosylation site (NIS) in 
position 108. For the nonglycosylated, mature protein, the molecular 
weight was calculated to be 36,000. The primary structure of this protein is 
comprised of five SCR domains. The three carboxyterminal repeats are 
nearly identical with the carboxyterminal sequence of the major factor H 
protein of Mr 150,000. The sequence coding for the two novel aminotermi-
nal SCR domains was shown to be unique for the 1.4 kb m R N A species in 
human liver by probing with primer extension c D N A clone H-69/2. 
In parallel to this work, we describe full length c D N A clones 
(pFH1.4a-f) derived from the 1.4 kb m R N A species which code for two 
distinct, presumably allelic transcripts (19). 
The clone described here was isolated from a different c D N A library and 
differs from the pFH1.4 clones and the 4.3 kb factor H transcript in the 
three carboxyterminal SCR domains and the 3' untranslated region (Table 
1). Thus, this c D N A represents another variant of the factor H-like protein 
encoded by the 1.4 kb mRNA species. 
Interestingly, no differences were observed in the 5' sequence of the 1.4 
kb m R N A coding for the two unique N-terminal domains, and no variation 
was found in the sequence of the different c D N A isolates representing the 
4.3 kb m R N A (H-46, this paper; R2a (8); pFH4.3 (9)). The derived amino 
acid sequence of H-69 differs in three positions to the peptide sequence 
encoded by pFH1.4b, and in five amino acid residues to the peptide 
encoded by pFH1.4a (see Table 1). Although the pFH sequences share two 
potential aminoglycosylation sites in position 108 and 176 with classical 
factor H , the variant encoded by H-69 has only the recognition sequence 
Table 1. Amino acid exchanges caused by nucleotide substitutions within three different 
variants of the factor H related 1.4 kb m R N A species and the 3' portion of the 4.3 kb m R N A 
of factor H (H-46) 
Pos. 139 Pos. 141 Pos. 178 Pos. 187 Pos. 239 Pos. 278 
pFH1.4a T A T = T y r GTG=Val A C G = T h r A C G = T h r TCA=Ser GCT=Ala 
pFH1.4b C A T = H i s CTG=Leu A C A = T h r A C G = T h r TCA=Ser GCT=Ala 
H-69 C A T = H i s CTG=Leu C A G = G l n C A G = G l n CTA=Leu GCT=Ala 
H-46 T A T = T y r GTG=Val A C G = T h r A C A = T h r TCA=Ser GTT=Val 
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( N W Q instead of N W T ) in position 176. It is likely that the function of the 
three carboxyterminal repeats in the polypeptides encoded by the 1.4 kb 
m R N A species differs from the one carried by the carboxyterminus of 
classical factor H . 
From a mouse liver c D N A library, four different classes of factor H 
related transcripts have recently been isolated and sequenced (27). Like the 
factor H related 1.4 kb m R N A species in man (18), these transcripts were 
found to be exclusively expressed in R N A preparations from liver tissue 
while the 4.4 kb factor H m R N A species of the mouse is also expressed in 
kidney, spleen, thymus and L cells (28). 
With respect to the functional importance of the protein encoded by the 
human 1.4 kb mRNA species, it was of interest to learn that one of these 
factor H-related transcripts of the mouse, represented by the c D N A clone 
13G1, shows remarkable similarities to the human 1.4 kb m R N A species: 
(i) Similar to the reported human 1.4 kb mRNA species, the m R N A 
which has given rise to 13G1, encodes a peptide of similar size consisting of 
five SCR motifs. The two aminoterminal domains were shown to be unique 
while the three following SCRs have stringent homology to the carboxyter-
minal domains of the mouse classical factor H . In contrast to the human 
factor H related transcript, the protein encoded by 13G1 contains two SCR 
repeats homologous to SCR 19 of the classical factor H followed by one 
SCR 20 homologous domain. 
(ii) As observed for the 1.4 kb m R N A in man, c D N A 13G1 shares a 
nearly identical 3' untranslated region with the 4.4 kb factor H mRNA. 
However, both use a different 5' untranslated region and leader sequence. 
Nucleotide and amino acid sequence comparison of the human and the 
mouse mRNA species shows that the polypeptide sequence is more con-
served than the nucleotide sequence. 
The polypeptide encoded by H-69 was investigated by the expression of 
a fusion protein (pAX-H-69) in E. coli in comparison with the homologous 
fragment of similar size derived from the carboxyterminus of the classical 
factor H c D N A (H-46 representing SCR 17-20). Whereas a polyclonal 
anti-factor-H-antibody detected both fusion proteins in a Western blot 
analysis, the monoclonal antibody 3D11 only stained the fusion protein of 
H-46, but not the fusion protein encoded by pAX-H-69. When mAb 3D11 
was used to look for a translational product of the 1.4 kb m R N A species in 
human plasma, classical factor H of M r 150,000 and in addition, two bands 
with a Mr of 39,000 and 37,000 were stained (see Fig. 5). This doublet was 
also seen with polyclonal antibodies directed against H and was detected 
regardless of whether the samples were run under reducing conditions or 
not. Moreover, the eucaryotic expression of both pFHl .4 variants 
(pFH1.4a and b) resulted in the synthesis of the two polypeptides of M r 
39,000 and 37,000 which were stained with mAb 3D11 (19). We therefore 
assume that the two smaller polypeptides detected in human plasma by 
mAb 3D 11 and polyclonal antibodies are encoded by the factor H related 
1.4 kb mRNA species and that the epitope recognized by mAb 3D 11 must 
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be localized on SCR 18-20. The mAb 3D11 failed to bind to the fusion 
protein encoded by pAX-H-69 whereas a similar fragment of classical 
factor H expressed with the same fusion partner and the eucaryotic 
expression products of pFHl.4a/b were stained, indicates that this reagent 
does not recognize the variant represented by the H-69 c D N A . 
The missing N-glycosylation site can not be responsible since procaryo-
tic expression products do not have this modification. Thus, the three 
amino acid residues at position 178, 188 and 239 with unique substitutions 
in the H-69-encoded polypeptide, are part of the epitope recognized by 
3D11. Screening human sera with polyclonal factor H reagents and the 
mAb 3D11 showed variations in the expression in the small factor H related 
polypeptides (unpublished results). 
Since the donor of the liver used for c D N A construction is not known, 
we could not directly test the plasma proteins. In conclusion, our results 
indicate variations in the factor H-related polypeptides encoded by the 1.4 
kb m R N A species detected by c D N A sequencing and by staining with the 
mAb 3D11. The posttranslational modification or processing event leading 
to the two polypeptides encoded by one 1.4 kb m R N A commonly detected 
in human sera, is not clear. I t still remains to be clarified whether this novel 
factor H related serum protein has any of the functions of classical factor H 
known so far. 
We are most grateful to Dr . R. B. SFM and Dr . A . J. D A Y , M R C Immunochemistry Unit , 
Oxford, U K , for helpful discussion. 
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